Drug intelligence / Profile preview

DS112

Development stage: Preclinical
Lead developer: DS Biopharma
Modality: Small Molecules

Overview

DS112 is an investigational small molecule developed by DS Biopharma for the treatment of multiple solid tumors. The drug is designed to target D40, a protein or signaling factor identified through DS Biopharma's research into bioactive lipid pathways. DS Biopharma specializes in the development of novel compounds derived from or targeting lipid signaling, and DS112 represents an application of this platform to oncology. The candidate is currently in early-stage development, aimed at inhibiting tumor growth and progression across a range of solid malignancies.

Targets

KNL1 (Kinetochore scaffold 1)

Beyond the preview

Go deeper on DS112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS112.

Explore the full profile